Paul Beresford

All healthcare professionals who carry out either Work Capability Assessments or Personal Independence Payment assessments undergo broad and thorough training in disability analysis, as well as training in specific conditions, including progressive conditions. Centre for Health and Disability Assessments, Atos Healthcare and Capita are required to conform to a rigorous set of quality and recruitment standards which are closely monitored by the Department for Work and Pensions.

While the Department has not made any formal assessment of the adequacy of referral services, the Department continues to support the National Health Service to recover all elective services, including for patients with skin conditions. This includes providing funding and setting direction through the elective recovery delivery plan published last year.

Most adult and paediatric dermatology services are commissioned locally through integrated care boards. However, to support patients with more complex or severe conditions, NHS England directly commissions some specialised services for example specialised adult and child dermatology clinics.

A recent NHS guide on referral optimisation for people with skin conditions outlines how systems can implement specialist advice and guidance. The approach enables local systems to embed personalised care, strengthen the primary and secondary care interface, and streamline collaboration between generalists and specialists so that more patients can be treated closer to home.

While the Department has not made any formal assessment, NHS England is working to ensure fair and equitable access to treatment for elective services in England, including for patients with inflammatory skin conditions.

NHS England’s outpatient recovery and transformation programme has introduced a number of initiatives, such as the virtual teledermatology two-week wait pathway, as well as patient-initiated follow-up and remote consultations, all of which provide opportunities to reduce the number of patients attending face-to-face appointments. This means capacity can be released for patients that need to be seen face-to-face, such as those with extensive inflammatory skin disease.

In addition, a document focusing on equity of access has recently been published and is available at the following link:

https://www.england.nhs.uk/long-read/ensuring-equity-of-access-to-care-when-redesigning-dermatology-pathways/

While the Department has not made a formal assessment of the potential merits of teledermatology or the impact of teledermatology on waiting list backlogs caused by COVID-19 in England, the Department continues to support the National Health Service in working to ensure the recovery and transformation of all elective services, including for patients with skin conditions. This includes providing record levels of funding and setting direction through the elective recovery delivery plan published last year. NHS England’s outpatient recovery and transformation programme published a teledermatology roadmap in 2021.

The outpatient recovery and transformation programme has also introduced a number of initiatives such as using advice and guidance and the virtual teledermatology two-week wait pathway, as well as patient initiated follow-up and remote consultations, all of which provide opportunities to reduce the number of patients attending face-to-face appointments. This means capacity can be released for patients that need to be seen face-to-face, such as those with extensive inflammatory skin disease.

Through these approaches, NHS providers are tackling the backlogs caused by the pandemic and transforming service provision for all patients.

The Department is supporting the National Health Service to improve outpatient services, including referral optimisation.

NHS England’s Outpatient Recovery and Transformation Programme runs a series of Action on Outpatients webinars to raise awareness of outpatient improvement initiatives. In December 2022, the series focused on outpatient referral optimisation, drawing on principles from NHS England guidance on referral optimisation for people with skin conditions, published September 2022.

The delivery of the MenACWY vaccine was interrupted by the closure of schools from 23 March 2020. Vaccine delivery was resumed as soon as possible and NHS England and NHS Improvement continue to ensure any students affected by this disruption have the opportunity to be vaccinated.

Vaccines against meningococcal B, given to children at one year old, were not paused during the pandemic. General practices continued to offer routine vaccination services, using social distancing and personal protective equipment. However, any child who did not receive their routine vaccinations during the pandemic remains eligible and general practitioners are able to provide the service to any child who has missed a vaccination.

No formal assessment has been made.

There has been no central formal impact assessment. Local systems delivering dermatology services carry out their own assessments.

The National Institute for Health and Care Excellence (NICE) is the independent, expert body responsible for developing authoritative, evidence-based guidance for the National Health Service. NICE has received a referral from NHS England and NHS Improvement to develop a guideline on atopic dermatitis or eczema in those aged over 12 years old, which will be commissioned for development in due course. There are no plans for NICE to develop a quality standard on atopic dermatitis in those aged over 12 years old.

There is no plan for this duty to entail undertaking an audit in relation to clinical nurse specialists working in prostate cancer, nor any other health professions or medical conditions.

The Department does not hold information on the number of clinical nurse specialists who specialise in urology and prostate cancer who plan to retire in the next 12 months. No audit has been undertaken an audit of the clinical nurse specialist workforce for either urology or prostate cancer.

We are working with NHS England and NHS Improvement, Health Education England and employers to determine our future workforce and people priorities which will inform the NHS People Plan and future workforce planning requirements in key areas such as cancer. In 2021/22 Health Education England is offering training grants for up to 250 nurses to become cancer nurse specialists and up to 100 nurses to become chemotherapy nurse specialists.

The Department does not hold information on the number of clinical nurse specialists who specialise in urology and prostate cancer who plan to retire in the next 12 months. No audit has been undertaken an audit of the clinical nurse specialist workforce for either urology or prostate cancer.

We are working with NHS England and NHS Improvement, Health Education England and employers to determine our future workforce and people priorities which will inform the NHS People Plan and future workforce planning requirements in key areas such as cancer. In 2021/22 Health Education England is offering training grants for up to 250 nurses to become cancer nurse specialists and up to 100 nurses to become chemotherapy nurse specialists.

The Department does not hold information on the number of clinical nurse specialists who specialise in urology and prostate cancer who plan to retire in the next 12 months. No audit has been undertaken an audit of the clinical nurse specialist workforce for either urology or prostate cancer.

We are working with NHS England and NHS Improvement, Health Education England and employers to determine our future workforce and people priorities which will inform the NHS People Plan and future workforce planning requirements in key areas such as cancer. In 2021/22 Health Education England is offering training grants for up to 250 nurses to become cancer nurse specialists and up to 100 nurses to become chemotherapy nurse specialists.

It has not proved possible to respond to the hon. Member in the time available before prorogation.

It has not proved possible to respond to the hon. Member in the time available before prorogation.

It has not proved possible to respond to the hon. Member in the time available before prorogation.

Travel status decisions are taken by Ministers informed by evidence including the Joint Biosecurity Centre’s analysis as well as other relevant information about the risk of the spread of variant. The advice, evidence and methodology which informs these decisions relates to on-going development of Government policy and therefore cannot be published at this time.

Providers of National Health Service care in England use the evidence cited and ensure that appropriate training is provided to health care workers in hand hygiene, providers also ensure that products are purchased that are consistent with the best available evidence. All healthcare workers have access to occupational health assessment and are referred for assessment and treatment in the event of developing skin complications. Using the guidelines, recommendations made by occupational health are followed by NHS providers as part of risk assessment and mitigation for the individual and the patient.

As Health and Safety Executive guidance for the general public states, and in line with WHO guidance, alcohol does not have to be “active ingredients” to be effective in hand sanitizer. The World Health Organization recommend that hand sanitiser should contain a minimum of 60% alcohol, but non-alcohol based sanitisers can also be effective when combined with other social distancing measures.

Providers of National Health Service care in England use the evidence cited and ensure that appropriate training is provided to health care workers in hand hygiene, providers also ensure that products are purchased that are consistent with the best available evidence. All healthcare workers have access to occupational health assessment and are referred for assessment and treatment in the event of developing skin complications. Using the guidelines, recommendations made by occupational health are followed by NHS providers as part of risk assessment and mitigation for the individual and the patient.

As Health and Safety Executive guidance for the general public states, and in line with WHO guidance, alcohol does not have to be “active ingredients” to be effective in hand sanitizer. The World Health Organization recommend that hand sanitiser should contain a minimum of 60% alcohol, but non-alcohol based sanitisers can also be effective when combined with other social distancing measures.

Providers of National Health Service care in England use the evidence cited and ensure that appropriate training is provided to health care workers in hand hygiene, providers also ensure that products are purchased that are consistent with the best available evidence. All healthcare workers have access to occupational health assessment and are referred for assessment and treatment in the event of developing skin complications. Using the guidelines, recommendations made by occupational health are followed by NHS providers as part of risk assessment and mitigation for the individual and the patient.

As Health and Safety Executive guidance for the general public states, and in line with WHO guidance, alcohol does not have to be “active ingredients” to be effective in hand sanitizer. The World Health Organization recommend that hand sanitiser should contain a minimum of 60% alcohol, but non-alcohol based sanitisers can also be effective when combined with other social distancing measures.

The following table shows how much Government funding was allocated to biomedical research into myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS) for financial years 2017-18, 2018-19 and 2019-20.

In addition to the funding set out above, the National Institute for Health Research, funded through the Department, and the Medical Research Council have recently announced a £3.2 million award to fund research into potential genetic connections to ME/CFS. The project will analyse samples from 20,000 people with ME/CFS to search for genetic differences that may indicate underlying causes or increase the risk of developing the condition.

Employers in the National Health Service are responsible for assessing risks to staff and addressing those risks. Any abuse of NHS staff and primary care contractors is unacceptable and should not be tolerated. Any form of abuse should be reported and primary care organisations should have no hesitation in involving the police. The role of NHS Protect was to develop national guidance to assist NHS organisations locally in their security management work. Comprehensive and detailed guidance is available to NHS employers to assist them in assessing and managing the risks accordingly and involving the police where appropriate.

The standards for security management work are imposed through the relevant clauses of the standard commissioning contract between commissioners and providers. It is commissioners’ responsibility to ensure that security management standards are met in accordance with the contract. NHS England is responsible for the standard commissioning contract and the clauses within it and the standards to which it refers.

No decisions have been taken yet on the funding or timing of the next Adult Dental Health Survey.